The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Overall response rate (ORR) as a potential surrogate for progression-free survival (PFS): A meta-analysis of metastatic non-small cell lung cancer (mNSCLC) trials submitted to the U.S. Food and Drug Administration (FDA).
Gideon Michael Blumenthal
No relevant relationships to disclose
Stella Karuri
No relevant relationships to disclose
Sean Khozin
No relevant relationships to disclose
Dickran Kazandjian
No relevant relationships to disclose
Hui Zhang
No relevant relationships to disclose
Lijun Zhang
No relevant relationships to disclose
Shenghui Tang
No relevant relationships to disclose
Rajeshwari Sridhara
No relevant relationships to disclose
Patricia Keegan
No relevant relationships to disclose
Richard Pazdur
No relevant relationships to disclose